Beneficiary name: |
ImmunoGenes Ltd. |
Project title: |
Development and commercialization of FcRn transgenic rabbit monoclonal antibody |
Grant amount of the contract: |
10 011 611 Ft |
Amount of support: |
60,4 % |
Project completion date: |
2020.07.31. |
Project identification number: |
VEKOP-2.1.7-15-2016-00231 |
Source: |
ERFA |
Country: |
Hungary |
A projekt tartalma:
With the grant, we have successfully set up the rabbit recombinant monoclonal antibody production protocol. To produce the antigen-specific rabbit monoclonal antibodies, rabbits were immunized and after the sorting, the variable regions were amplified from a single cell. Using our established protocol, more than thirty different rabbit monoclonal antibodies were generated. These were tested by both rabbit antibody-specific and antigen-specific ELISA, and antigen-specific rabbit monoclonal antibody was generated. A transfection protocol was also set up to increase the number of recombinant antibodies produced. In addition, the rabbit variable regions were integrated into vectors containing a mouse constant region, so called, chimeric antibodies with a constant region of murine origin were prepared. In many cases, this may be more advantageous than an antibody with a rabbit constant region. With the results obtained, we have generated a method by which we are able to produce recombinant rabbit monoclonal antibodies. From now on, in addition to transgenic mice, we can add a new sector, which is to successfully produce monoclonal antibodies against a given antigen with transgenic rabbits, which increases the chances of producing a high-quality antibody for us and our customers.